Ionis Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
Commercial momentum: TRYNGOLZA exceeded expectations with Q4 net sales of $50M and $108M for 2025 while DAWNZERA is seeing early adoption, full conversion from trials, and a management-estimated peak sales potential of $500M, with European launches underway. Olezarsen sHTG filing and efficacy: Phase 3 data showed up to a 72% triglyceride reduction and an 85% reduction in adjudicated acute pancreatitis, Ionis has breakthrough designation, submitted a supplemental NDA late 2025, requested priority review, and is planning to be launch-ready by June pending FDA timing. Financials and 2026 outlook: 2025 revenue was $944M (46% commercial), 2026 guidance of $800–825M reflects a one-time $280M license fee in 2025 (management says ~20% underlying growth), with an expected non-GAAP operating loss of $500–550M, about $1.6B cash at year-end 2026, and a goal of cash-flow breakeven by 2028. Interested in Ionis Pharmaceuticals, Inc.? Here are five stocks we like better. Are These 5 Underval
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis Pharmaceuticals Inc (IONS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals (IONS) had its "buy" rating reaffirmed by Needham & Company LLC.MarketBeat
- Ionis Pharmaceuticals (IONS) had its "outperform" rating reaffirmed by Royal Bank Of Canada.MarketBeat
- Ionis Pharmaceuticals: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs [Yahoo! Finance]Yahoo! Finance
IONS
Earnings
- 2/25/26 - Miss
IONS
Sec Filings
- 2/25/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- 2/13/26 - Form 4/A
- IONS's page on the SEC website